Isa Ahmed Ahmed Alsharoqi

Dr. Isa Ahmed Ahmed Alsharoqi

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
RARaed A Alroughani
Raed A Alroughani
HAHany M Aref
Hany M Aref
SBSaeed A Bohlega
Saeed A Bohlega
MDMaurice P Dahdaleh
Maurice P Dahdaleh
IFImed Feki
Imed Feki
BBBassem I Beirut
Bassem I Beirut
Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multiple sclerosis (MS). Natalizumab is recommended for patients who fail first-line disease-modifying therapy or who have very active disease. Progressive multifocal leukoencephalopathy is a rare, serious adverse event associated with natalizumab.

29 June 2026 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
IAIsa Ahmed Ahmed Alsharoqi
Isa Ahmed Ahmed Alsharoqi
AAAbdulla I. Salem Alsharoqi
Abdulla I. Salem Alsharoqi
SBSaeed A. Bohlega
Saeed A. Bohlega

10 September 2026 in Research Square
Verified
Preprint
Open access
PDF file
IAIsa Ahmed Ahmed Alsharoqi
Isa Ahmed Ahmed Alsharoqi
LALayla Mohamed Ali
Layla Mohamed Ali
AKAyman Khalil
Ayman Khalil
SASayed Mohamed Alsaffar
Sayed Mohamed Alsaffar
BABader Mohamed Ali
Bader Mohamed Ali
AAAdel Aljishi
Adel Aljishi
Background Bahrain’s 2011–2013 multiple sclerosis (MS) registry established the country’s first epidemiological baseline using the 2010 McDonald criteria. Since then, diagnostic criteria, MRI access, specialist care, and follow-up have evolved, while Bahrain and Gulf Cooperation Council (GCC) studies suggest HLA and non-HLA susceptibility signals. The present analysis links the foundational baseline to March 2026 registry-based case ascertainment and a one-year new-diagnosis count, allowing contemporary prevalence and incidence to be considered together while preserving the distinction between registry ascertainment and a formal population survey. Objective To compare the 2013 and 2026 clinically recognized MS burden among Bahraini citizens, quantify contemporary crude registry-based prevalence and incidence, and contextualize the findings with emerging Bahraini and GCC genetic and environmental evidence. Materials and Methods This retrospective registry-based descriptive analysis included 287 Bahraini patients fulfilling the 2010 McDonald criteria and identified through Salmaniya Medical Complex between 1 July 2011 and 31 October 2013. The March 2026 count combined Salmaniya Medical Complex and National Bank of Bahrain Multiple Sclerosis Centre records. Crude prevalence was estimated from 876 actively followed patients using a Bahraini-citizen denominator of 747,500, with sensitivity analysis across 745,000–755,000. From March 2025 to March 2026, 48 newly diagnosed Bahraini patients were registered; crude registry-based incidence and an exact Poisson 95% confidence interval (CI) were calculated. Only aggregate data were analyzed. Contemporary GCC epidemiology and relevant diagnostic, environmental, genetic, and treatment evidence were reviewed narratively. Results The foundational cohort had a female-to-male ratio of 2.49:1, mean age at onset of 35 ± 10.2 years, median Expanded Disability Status Scale score of 2.0, reported prevalence of 59.9 per 100,000 Bahraini citizens (recalculated 95% CI, 53.0–66.8), and annual incidence of 5.8 per 100,000 (95% CI, 2.8–8.87) during 2012–2013. By March 2026, 876 patients were actively followed, 589 more than the foundational count and 3.05-fold that count. Estimated crude registry-based prevalence was 117.2 per 100,000 (95% CI, 109.4–125.0; sensitivity range, 116.0–117.6). The 48 newly diagnosed patients yielded a crude registry-based incidence of 6.4 per 100,000 (95% CI, 4.7–8.5). Conclusion Bahrain’s clinically recognized MS burden has increased substantially, while the contemporary one-year incidence estimate remains broadly similar to the earlier estimate. This pattern is compatible with a combination of epidemiological change, cumulative prevalence, improved ascertainment, diagnostic sensitivity, survival, and specialist follow-up rather than a proportional rise in annual new diagnoses. Differences in diagnostic eras and ascertainment preclude direct causal attribution. Prospective national registration integrating clinical, imaging, treatment, environmental, and genetic data is needed to define the evolving burden and its determinants.

24 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
IAIsa Ahmed Ahmed Alsharoqi
Isa Ahmed Ahmed Alsharoqi
ESEslam Mahmoud shosha
Eslam Mahmoud shosha
SBSaeed A. Bohlega
Saeed A. Bohlega
Background: Inflammatory demyelinating diseases of the central nervous system, including multiple sclerosis (MS), aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG-positive NMOSD), seronegative NMOSD, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), recurrent optic neuritis, longitudinally extensive transverse myelitis (LETM), and pediatric acquired demyelinating syndromes, are increasingly recognized across the Gulf Cooperation Council (GCC) countries. Regional evidence remains fragmented, retrospective, disease-specific and unevenly distributed across Bahrain, Saudi Arabia, the United Arab Emirates, Kuwait, Qatar and Oman. Existing data suggest expanding recognition of MS and related demyelinating disorders, but the region lacks a unified prospective platform capable of capturing diagnostic criteria version, antibody testing, imaging, treatment access, longitudinal disability, visual outcomes, pediatric development, real-world treatment safety, pharmacovigilance, health-service equity and precision-management variables across public and private care pathways.Objectives: This strategic framework proposes a unified GCC Demyelinating Disease Registry to transform fragmented evidence into a prospective, interoperable, ethically governed and policy-relevant learning health-system platform for precision neuroimmunology across the Arabian Gulf.Proposed design: The registry would use a modular architecture incorporating a core minimum dataset and disease-specific modules for MS, NMOSD, MOGAD, optic neuritis, LETM, pediatric acquired demyelination, imaging, antibody testing, treatment, relapse, disability, visual outcomes, quality of life, pregnancy, vaccination, infection and long-term safety. Optional extended modules would support approved studies of immunopathology, genetic susceptibility, gene-environment interaction, pharmacogenomics, biomarkers, health economics and therapy response. The technical design should use a pragmatic hybrid model: REDCap or an equivalent electronic case-report form for clinical data entry, an Observational Medical Outcomes Partnership-compatible analytical backend, FAIR-aligned metadata, standardized vocabulary mapping, Observational Health Data Sciences and Informatics-compatible analytics, and privacy-preserving federated reporting. Governance would require national coordinating hubs, hospital registry nodes, pediatric and laboratory-imaging panels, a FAIR-OMOP technical board, transparent publication rules, patient and family input, and explicit protection of national data sovereignty.Expected scientific and clinical impact: A unified GCC registry would enable accurate disease ascertainment, antibody-testing harmonization, diagnostic reclassification, real-world treatment evaluation, pediatric outcome tracking, pharmacovigilance, clinical-trial readiness, health-economic analysis, clinical decision-support development and policy decision-making. It would address GCC-specific challenges, including multinational coordination, expatriate mobility, variable laboratory access, cultural considerations, data sovereignty, shared and partially overlapping ancestral and environmental backgrounds, and equity in biologic treatment access. If adopted across all six member states, the registry could plausibly enroll several thousand patients within five years and, with mature national coverage including expatriate residents, could over the longer term approach the majority of the region's prevalent demyelinating-disease population.Conclusion: A unified GCC Demyelinating Disease Registry would provide the region with a practical, prospective and interoperable infrastructure for surveillance, real-world treatment evaluation, pharmacovigilance, pediatric outcome tracking, clinical decision support and precision-neuroimmunology research. By building on prior Gulf registry experience without duplicating disease-specific initiatives, the proposed framework could transform fragmented national evidence into a coordinated GCC-wide learning health-system platform and a scalable model for other Middle Eastern and North African health systems.

19 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
IAIsa Ahmed Ahmed Alsharoqi
Isa Ahmed Ahmed Alsharoqi
SBSaeed A. Bohlega
Saeed A. Bohlega
Background: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (MENACTRIMS) has developed congresses, clinical guidance, registry research, training, certification, and advocacy partnerships. Evaluating this infrastructure requires distinctions between organizational activity, implementation, and attributable benefit.Objectives: To characterize documented achievements, compare the geographic distribution of major functions, identify public reporting gaps, and propose a measurable regional learning-health-system roadmap.Methods: A structured public-document audit and targeted literature synthesis covered activities from 2014 through 23 August 2026, with a documented update on 16 October 2026. Sources were classified by provenance and evidentiary purpose, without performance scoring. Geographic coverage used a fixed 19-jurisdiction Middle East and North Africa frame. Reported attendance terms and registry denominators were preserved.Results: Ten completed congresses were identified; seven with exact headline attendance had a median of 934 participants (interquartile range 761.5–1006.5). Seven congresses were hosted in the United Arab Emirates. Five major guideline outputs or revisions, multicountry registry studies, policy endorsements, and traceable grant- and fellowship-linked publications demonstrated sustained scientific activity. The public registry headline was 15,387, compared with 14,438 enumerable center records; variable displays represented 78.8%–93.9% of the headline, without establishing true field completeness. Iran, Egypt, and Kuwait contributed 75.4% of enumerable records. Council listings covered 15/19 jurisdictions, registry centers 8/19, and certified centers 2/19. Certification standards already specify three-year renewal and prefer registry participation; fellowship terms require reporting and career follow-up. Aggregated results of these processes were less readily ascertainable.Conclusions: MENACTRIMS has established substantial regional infrastructure. Differing geographic distributions identify questions about coordination and opportunity but do not establish organizational failure. A phased roadmap for 2027–2035 should build on existing systems through denominator reconciliation, publicly reported program outcomes, guideline-linked quality improvement, and meaningful patient and professional participation. Public-source limitations and the non-systematic synthesis preclude causal attribution of regional patient outcomes to MENACTRIMS.

17 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
IAIsa Ahmed Ahmed Alsharoqi
Isa Ahmed Ahmed Alsharoqi
BMBader Ali Mohamed
Bader Ali Mohamed
AAAbdulla I Salem Alsharoqi
Abdulla I Salem Alsharoqi
SBSaeed A Bohlega
Saeed A Bohlega
Background: Progressive multiple sclerosis (MS) requires outcomes that represent consequential deterioration and support valid treatment comparisons. Broader domain coverage, high reliability, and more progression events address different aspects of endpoint performance. Objectives: To evaluate established and emerging outcomes, distinguish progression ascertainment from randomized treatment discrimination, and derive a practical Gulf Cooperation Council (GCC) monitoring dataset. Methods: Targeted public retrieval through 8 September 2026 supported a purposive synthesis of 19 randomized trial programmes, linked measurement and composite-endpoint studies, existing outcome frameworks, and regional publications. Measurement properties and randomized treatment discrimination were examined separately. Within-trial comparisons preserved effect measures, confirmation periods, and analytical status. The review did not undertake exhaustive database searching, independent duplicate review, or de novo comparative pooling. Results: EDSS-primary trials established treatment benefits in several progressive-MS populations, while performance measures revealed complementary domain information. ASCEND had a negative primary composite but a substantial secondary dexterity signal (9HPT odds ratio 0.56, 95% CI 0.40–0.80). ORATORIO-HAND prospectively demonstrated benefit on EDSS-or-9HPT progression (hazard ratio 0.70, 95% CI 0.57–0.86). Neither result establishes universal composite superiority. Measurement studies showed that high reliability can coexist with detectable-change boundaries exceeding commonly used progression thresholds. Contemporary composite analyses further distinguish broader event capture from stronger treatment contrasts, and OR-type from AND-type definitions. A four-level architecture integrates neurological disability, domain performance, patient-relevant function, and biological or digital observations. Building on existing outcome sets and registry infrastructure, the proposed GCC dataset separates baseline information, eight routine assessment modules, conditional investigations and confirmation, and optional extensions. Conclusions: Endpoint adequacy is specific to the population, construct, measurement process, and estimand. Harmonized, dated multidomain observations can strengthen progression assessment without assuming that every added measure improves statistical power. The GCC proposal provides an evidence-derived specification for prospective feasibility and clinical-utility evaluation.